Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Investigation of the Mechanism of Action by Comprehensive Transcriptome Analysis

ABSTRACT: To elucidate the SLFN12 RNase effector function, we used whole-genome microarray expression profiling as a discovery platform to identify genes that potentially drive anticancer efficacy upon OPB-171775 treatment. The compound was treated for 8 or 24 hours in control PFSK1 cells and siSLFN12 knockdown PFSK1 cells. Gene set enrichment analysis (GSEA) revealed a significant enrichment of gene sets associated with ribosomal function and the endoplasmic reticulum (ER) stress response in OPB-treated cells compared to control cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE241312 | GEO | 2024/05/14

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death [tRNA seq]

Project description:Velcrin compounds kill cancer cells expressing high levels of phosphodiesterase 3A (PDE3A) and Schlafen family member 12 (SLFN12) by inducing complex formation between these two proteins, but the mechanism of cancer cell killing by the PDE3A–SLFN12 complex is not fully understood. Here, we report that the physiological substrate of SLFN12 RNase is tRNALeu(TAA). SLFN12 selectively digests tRNALeu(TAA), and velcrin treatment promotes the cleavage of tRNALeu(TAA) by inducing PDE3A–SLFN12 complex formation in vitro. We found that distinct sequences in the variable loop and acceptor stem of tRNALeu(TAA) are required for substrate digestion. Velcrin treatment of sensitive cells results in downregulation of tRNALeu(TAA), ribosome pausing at Leu-TTA codons and global inhibition of protein synthesis. Velcrin-induced cleavage of tRNALeu(TAA) by SLFN12 and the concomitant global inhibition of protein synthesis thus define a new mechanism of apoptosis initiation.

2022-09-01 | GSE185827 | GEO

Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death [Ribo-Seq]

2022-09-01 | GSE185826 | GEO

Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death [RNA-Seq]

2022-09-01 | GSE185822 | GEO

Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase

Project description:Garvie CW, Wu X, Papanastasiou M, Lee S, Fuller J, Schnitzler GR, Horner SW, Baker A, Zhang T, Mullahoo JP, Westlake L, Hoyt SH, Toetzl M, Ranaghan M, de Waal L, McGaunn J, Kaplan B, Piccioni F, Yang X, Lange M, Tersteegen A, Raymond D, Lewis TA, Carr SA, Cherniack AD, Lemke C, Meyerson M, Greulich H. 2021. DNMDP and related compounds, or "velcrins", induce complex formation between the phosphodiesterase PDE3A and the SLFN12 protein, leading to a cytotoxic response in cancer cells that express elevated levels of both proteins. The mechanisms by which velcrins induce complex formation, and how the PDE3A-SLFN12 complex causes cancer cell death, are not fully understood. Here, we show that PDE3A and SLFN12 form a heterotetramer stabilized by binding of DNMDP. Interactions between the C-terminal alpha helix of SLFN12 and residues near the active site of PDE3A are required for complex formation, and are further stabilized by interactions between SLFN12 and DNMDP. Moreover, we demonstrate that SLFN12 is an RNase, that PDE3A binding increases SLFN12 RNase activity, and that SLFN12 RNase activity is required for DNMDP response. This new mechanistic understanding will facilitate development of velcrin compounds into new cancer therapies.

2021-06-14 | MSV000087620 | MassIVE

E-GEOD-66493

Project description:Transcription profiling by array of human U87 cells treated with cytotoxic anticancer drug cisplatin or a ruthenium-based compound for 6 or 24 hours compared to untreated controls

2025-01-24 | E-GEOD-66493 | ExpressionAtlas

Improving gene set enrichment analysis (GSEA) by using regulation directionality

Project description:Improving gene set enrichment analysis (GSEA) by using regulation directionality

| PRJNA860153 | ENA

RNA sequencing of intestinal enterocytes pre- and post-Roux-en-Y gastric bypass reveals alteration in gene expression related to enterocyte differentiation, restitution, and obesity

Project description:Background: The intestinal lining renews itself in a programmed fashion that can be affected by adaptation to surgical procedures such as gastric bypass. Results: RNA sequencing suggested significant decreases of gene expression associated with G2/M DNA damage checkpoint regulation of the cell cycle pathway, and significant increases in gene expression associated with CDP-diacylglycerol biosynthesis pathway TCA cycle II pathway, and pyrimidine ribonucleotide salvage pathway after RYGB. Since SLFN12 is reported to influence enterocytic differentiation, we stained mucosa for SLFN12 and observed increased SLFN12 immunoreactivity. We investigated SLFN12 overexpression in HIEC-6 and FHs 74 Int intestinal epithelial cells and observed similar increased expression of the following genes that were also increased after RYGB: HES2, CARD9, SLC19A2, FBXW7, STXBP4, SPARCL1, and UTS. Conclusions: Our data suggests that RYGB promotes SLFN12 protein expression, cellular mechanism and replication pathways, and genes associated with differentiation and restitution (HES2, CARD9, SLC19A2) and obesity-related genes (FBXW7, STXBP4, SPARCL1, UTS).

2022-11-01 | GSE214758 | GEO

E-GEOD-56940

Project description:Expression data for T47D cells treated with 2mM hydroxyurea

2025-01-24 | E-GEOD-56940 | ExpressionAtlas

E-GEOD-55123

Project description:Expression data from untreated and Aza treated AML3 cells

2025-01-24 | E-GEOD-55123 | ExpressionAtlas

E-GEOD-57728

Project description:Expression data from AsPC1 cells treated with ICG-001

2025-01-24 | E-GEOD-57728 | ExpressionAtlas